Supply of products by Generic Health Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods to ensure their safety, quality, and efficacy. The Act establishes a framework for the control of therapeutic goods, including medicines, medical devices, and blood and blood components. The Therapeutic Goods (14 and 14A Notice) Section 14 and 14A Notice 2013, issued on May 14, 2013, by the delegate of the Secretary of the Department of Health and Ageing, was introduced to manage the supply of specific products that do not conform with the dissolution requirements of the United States Pharmacopeia (USP) monograph for Raloxifene Hydrochloride tablets. This consent ensures that the products supplied by Generic Health Pty Ltd meet the agreed dissolution limits using the agreed dissolution test, thus maintaining the quality and safety standards set by the Act. The policy objective of this notice, as stated in the Act, is to safeguard public health by ensuring that therapeutic goods supplied in Australia meet the necessary standards for quality and safety. This includes providing a mechanism for the supply of products that do not fully comply with certain pharmacopeial standards, provided that alternative compliance measures are met. This legislative action ensures that therapeutic goods continue to be made available to consumers while upholding the regulatory standards designed to protect health and wellbeing.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, and blood products. This Act applies to all entities involved in the supply, advertising, and sponsorship of therapeutic goods within the Australian jurisdiction, including manufacturers, importers, sponsors, and distributors. The Act operates at the Commonwealth level, meaning it has national reach across Australia, thereby ensuring a unified approach to the regulation of therapeutic goods throughout the country. Certain exclusions and exemptions exist within the Act, particularly concerning goods used for personal or domestic purposes, and research activities under specific conditions. Additionally, the Act allows for the extension and restriction of its application through subordinate instruments, enabling the incorporation of further specifications and detailed regulatory requirements. In the context of the Gazette notice issued on May 14, 2013, the Act's application is specifically directed towards the supply of raloxifene hydrochloride tablets by Generic Health Pty Ltd. The notice provides consent for the supply of these products, despite their non-compliance with the dissolution requirements of the USP monograph, on the condition that they meet agreed dissolution limits using a specified dissolution test. This instance illustrates how the Act can be flexibly applied to allow for the supply of therapeutic goods under controlled conditions, thereby balancing regulatory oversight with practical considerations in the pharmaceutical industry.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) allow the delegate of the Secretary of the Department of Health and Ageing to provide consent for the supply of therapeutic goods that do not fully comply with certain standards. Specifically, section 14 permits the delegate to consent to the supply of goods that do not meet the dissolution requirements of the United States Pharmacopeia (USP) monograph. Section 14A further specifies that such consent is conditional upon the therapeutic goods conforming to agreed dissolution limits using an agreed dissolution test. In this instance, the delegate granted consent for the supply of raloxifene hydrochloride tablets by Generic Health Pty Ltd, despite the products not meeting the dissolution requirements outlined in the USP monograph. However, this consent is conditional upon the products conforming to the agreed dissolution limits using the agreed dissolution test. The obligations imposed by the Act on Generic Health Pty Ltd and the delegate of the Secretary include ensuring that the supplied products meet the dissolution limits as stipulated in the conditions of consent. This entails that Generic Health Pty Ltd must adhere to the agreed dissolution test to verify compliance with the specified dissolution limits. Furthermore, the delegate of the Secretary must ensure that the consent provided is strictly adhered to, and any non-compliance must be reported and addressed promptly. The Act mandates that the therapeutic goods supplied must meet these standards to ensure public safety and efficacy. Failure to comply with the conditions set forth in the consent may lead to various civil and criminal consequences. Under the Act, breaches of the conditions of consent can result in legal action against the entity supplying the non-compliant therapeutic goods. Specifically, section 33D of the Act outlines the penalties for breaches, which include fines and potential imprisonment. For corporations, the maximum penalty can be substantial, reflecting the seriousness of non-compliance with therapeutic goods regulations. Additionally, ongoing non-compliance could result in the revocation of the consent, leading to further legal ramifications for the entity involved. In summary, the Therapeutic Goods Act 1989, through sections 14 and 14A, allows the delegate of the Secretary to provide conditional consent for the supply of therapeutic goods that do not fully comply with certain standards. This consent is contingent upon the products meeting agreed dissolution limits. Generic Health Pty Ltd must ensure that the supplied raloxifene hydrochloride tablets meet these conditions. Failure to comply can result in significant civil and criminal penalties, underscoring the importance of adhering to the Act's requirements.